Tag Archives: healthcare

Patients Suffering from Gaucher’s Disease Deserve Better

scientist-eyedropper

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing a frontier of unmet medical need [NCATS, NIH]. The challenges for drug development generally—long and costly research and development timelines—are exacerbated by the inherently small patient populations affected by rare diseases. These patients can be difficult to identify and geographically dispersed and their clinical presentation can be quite disparate, complicating the design and recruitment for clinical trials used to determine Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

New York Times Building

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Greenwood Highlights Need for Bold Action to Address Alzheimer’s

Jim Greenwood

Last week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), participated and spoke at the #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit hosted at the United Nations in New York City. The day-long event explored links between Traumatic Brain Injury and Alzheimer’s Disease and featured leading policy experts, biotechnology entrepreneurs, academics,  investment firms, medical researchers, diplomats and professional athletes. The event was hosted by Brewer Sports International (BSI), a multi-faceted global Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Treating Hepatitis C: Too Costly Not to Act

CHI

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act – by California Healthcare Institute’s Todd Gillenwater on the value of breakthrough Hepatitis C medicines that cure the disease in the majority of patients. As Gillenwater asserts, “New hepatitis C drugs mark a paradigm shift – from a model of somewhat iffy but costly chronic care to a model of short-term curative treatment with equal or slightly lower costs paid Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Partners for Healthy Dialogues: Letter to CMS

Partners for Health Dialogues

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in a letter to the Center for Medicare and Medicaid Services highlighting both their shared commitment to sunshine and the importance of context in the upcoming data release.  As BIO CEO Jim Greenwood said in a Q&A with P4HD: “We believe that part of CMS’s public service function in this area should be to help improve the public’s understanding of the need for Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,